Retatrutide: A Literature Course in Six Modules

How this course is organised

This course reviews the published retatrutide literature in six modules: what the compound is, how its mechanism is described, what outcomes individual studies reported, what adverse events appeared in trial reports, what pharmacokinetic data exist, and what its regulatory status is. Every module ends with a short statement of the limits of that evidence, because the boundaries of a trial matter as much as its headline numbers. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or treatment. Nothing here describes a protocol, and no outcome described below should be read as a promise.

Module 1: What retatrutide is and how it has been studied

Definition and class. Retatrutide is a synthetic peptide-based agonist that engages three incretin and glucagon-family receptors in a single molecule: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is therefore described in the literature as a "triple-hormone-receptor agonist" or "triple agonist", a class distinct from single GLP-1 receptor agonists and from dual GIP/GLP-1 agonists, as outlined in a 2025 narrative review of retatrutide in obesity pharmacotherapy (PMID 40563436) and a 2024 pharmacology review (PMID 39515565).

Origin and naming. The molecule entered the literature under the development code LY3437943, and the discovery-to-clinical-proof-of-concept report in Cell Metabolism described its design as a novel triple glucagon, GIP and GLP-1 receptor agonist intended for glycaemic control and weight lowering (PMID 35985340). Later clinical publications use the name retatrutide.

Forms studied. Across the published trials the compound was given as a once-weekly subcutaneous injection; a 2024 systematic review and meta-analysis was framed specifically around "once-weekly subcutaneous retatrutide" and pooled randomised trials using that route and interval (PMID 39318607). No oral, nasal or transdermal retatrutide form appears in the verified literature summarised here.

Populations studied. Published work spans early-phase pharmacology in people with type 2 diabetes (PMID 36354040), a phase 2 trial in adults with obesity (PMID 37366315), a phase 2 trial in adults with type 2 diabetes (PMID 37385280), a phase 2a trial in metabolic dysfunction-associated steatotic liver disease (PMID 38858523), a phase 3 trial in type 2 diabetes managed with diet and exercise (PMID 42250575), and a registrational programme whose design paper covers obesity, obstructive sleep apnoea and knee osteoarthritis (PMID 41090431).

Limits of the evidence in Module 1

The published record describes adults enrolled in industry-sponsored trials with defined entry criteria. It does not characterise the compound in adolescents, in pregnancy, in people outside trial eligibility windows, or in any non-injectable form. Descriptions of chemical class are drawn from review and discovery papers, not from independent structural verification of material circulating outside clinical supply chains.

Module 2: Mechanism as described in the literature

The Cell Metabolism discovery report characterised retatrutide as a single peptide with agonist activity at all three target receptors and traced that pharmacology from in vitro characterisation through animal models to a first proof-of-concept in humans, where glycaemic and weight-related effects were measured (PMID 35985340). Review articles describe the three arms of the mechanism in the following terms.

• GLP-1 receptor component. Reviews describe glucose-dependent insulin secretion, slowed gastric emptying and reduced appetite as the canonical GLP-1 receptor effects contributing to weight and glycaemic change (PMID 40563436).
• GIP receptor component. The same review literature describes GIP receptor activation as adding to insulin secretion and to central appetite regulation, and as a component that may modify tolerability relative to GLP-1 alone (PMID 39515565).
• Glucagon receptor component. Reviews attribute an energy-expenditure and hepatic-lipid dimension to glucagon receptor agonism, which is the rationale reviewers give for studying the molecule in steatotic liver disease as well as obesity (PMID 40563436, PMID 39515565).

That mechanistic rationale was tested directly in a phase 2a trial in which researchers measured liver fat content in participants with metabolic dysfunction-associated steatotic liver disease and reported dose-related reductions in liver fat at 24 weeks compared with placebo (PMID 38858523). A body-composition substudy in people with type 2 diabetes used imaging endpoints to separate fat mass from lean mass change during retatrutide treatment (PMID 40609566).

Limits of the evidence in Module 2

Mechanism statements in reviews are interpretive syntheses, not measurements in individual participants. Trials measured downstream endpoints — weight, HbA1c, liver fat, body composition — rather than isolating the contribution of each receptor in humans. The relative weight of GIP, GLP-1 and glucagon signalling to any given outcome in people is not resolved by the papers cited here.

Module 3: Reported outcomes by study

The table below summarises design and reported endpoints. Doses and effects are attributed to the specific publication that reported them.

Two pooled analyses sit above the individual trials. A 2025 systematic review and meta-analysis of randomised controlled trials examined efficacy and safety of retatrutide for obesity treatment and reported greater weight reduction with retatrutide than placebo alongside a higher frequency of gastrointestinal adverse events (PMID 40291085). A 2024 systematic review and meta-analysis of once-weekly subcutaneous retatrutide reported effects on body weight and on metabolic markers across the randomised evidence available at that time (PMID 39318607).

Limits of the evidence in Module 3

Most quantified outcomes come from phase 1b and phase 2 trials lasting 12 to 48 weeks, with dose-escalation schedules and trial-level lifestyle support that are inseparable from the numbers reported. Group means do not describe individual trajectories, placebo groups also changed, and the meta-analyses pooled a small number of studies. Endpoints were surrogate or intermediate measures — weight, HbA1c, liver fat, body composition — not long-term clinical event rates.

Module 4: Retatrutide Side Effects: What Studies Report

Adverse events in the retatrutide literature cluster around the gastrointestinal tract and, in some reports, heart rate.

• Gastrointestinal events. In the phase 2 obesity trial, researchers reported that the most common adverse events were mild-to-moderate gastrointestinal events that were dose-related, including nausea, vomiting, diarrhoea and constipation (PMID 37366315). The phase 1b multiple-ascending-dose trial in type 2 diabetes similarly reported gastrointestinal adverse events such as nausea, vomiting and diarrhoea as the most frequent findings (PMID 36354040), and the phase 2 type 2 diabetes trial reported a comparable gastrointestinal profile alongside its efficacy results (PMID 37385280).
• Pooled adverse-event signal. The 2025 meta-analysis of randomised trials in obesity reported that gastrointestinal adverse events occurred more often with retatrutide than with placebo (PMID 40291085).
• Heart rate. The phase 2 obesity trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter (PMID 37366315), and heart-rate changes were also among the observations in the earlier multiple-ascending-dose work (PMID 36354040).
• Body-composition considerations. The body-composition substudy in type 2 diabetes reported changes in lean mass as well as fat mass, an observation reviewers discuss when interpreting large weight reductions (PMID 40609566).
• Review-level summary. Narrative reviews summarise the tolerability profile as dominated by dose-related gastrointestinal effects managed in trials through gradual dose escalation (PMID 40563436, PMID 39515565).

Limits of the evidence in Module 4

Adverse-event data come from monitored trials in which participants were screened, titrated and followed by clinicians, and in which rare events may not appear at all given sample sizes in the hundreds. Trial durations of up to 48 weeks in the phase 2 obesity study cannot describe multi-year safety. Reported frequencies belong to the specific doses, escalation schemes and populations studied, and cannot be transferred to other settings, other materials or other dosing patterns.

Module 5: Pharmacokinetics where data exist

The pharmacokinetic picture in the verified literature is thin but consistent with the dosing interval used in trials. The discovery and proof-of-concept report described the molecule's design for extended exposure and presented first-in-human pharmacokinetic characterisation supporting once-weekly administration (PMID 35985340), and the phase 1b multiple-ascending-dose trial evaluated escalating weekly subcutaneous doses over 12 weeks in people with type 2 diabetes (PMID 36354040). Every subsequent clinical publication in this list used a once-weekly subcutaneous schedule, including the pooled analysis framed explicitly around once-weekly subcutaneous administration (PMID 39318607).

Trial designs also embedded gradual escalation rather than immediate exposure to maintenance doses: the phase 2 obesity trial assigned groups that began at lower starting doses before escalating toward maintenance doses of 4, 8 or 12 mg weekly (PMID 37366315), and the phase 2 type 2 diabetes trial likewise studied a range from 0.5 mg to 12 mg weekly against placebo and dulaglutide 1.5 mg (PMID 37385280).

Limits of the evidence in Module 5

Detailed parameters — absorption, distribution, metabolism, elimination pathways, drug–drug interactions, behaviour in renal or hepatic impairment — are not established by the abstracts summarised here. Pharmacokinetics were measured in trial participants receiving pharmaceutical-grade study drug; they say nothing about material of unknown provenance, concentration or purity.

Module 6: Regulatory status stated factually

Retatrutide is described throughout the cited literature as an investigational agent under clinical development. Papers published through the phase 3 stage present it as being evaluated for efficacy and safety rather than as an approved therapy (PMID 42250575), and the registrational programme design paper describes trials intended to support potential marketing applications in obesity, obstructive sleep apnoea and knee osteoarthritis (PMID 41090431).

Several regulatory facts follow from that status. An investigational molecule has no approved product labelling, no approved indication, no approved dose and no approved route outside of clinical trial protocols. Vials of peptides sold with "research use only" (RUO) labelling are not medicines: RUO designation indicates material intended for laboratory investigation, not for administration to humans, and such material is not reviewed for identity, potency, sterility or endotoxin content the way a licensed medicine is. In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act is generally tied to drug substances that are components of approved drugs, the subject of a USP monograph, or included on FDA bulk substance lists; a molecule that has not received FDA approval does not meet those conditions on the basis of investigational trial data alone. Regulatory classification also varies by country and can change as review processes proceed. This section describes published and publicly stated regulatory frameworks for educational purposes and is not legal advice; questions about the legal status of any substance in a particular jurisdiction belong to a qualified attorney or the relevant regulator.

Limits of the evidence in Module 6

Regulatory status is a moving target, and the literature captured here reflects the development stage at the time of each publication rather than the position of any agency today. Approval decisions, indication wording and scheduling are set by regulators, not by trial publications.

What the studies did not test

Reading the retatrutide literature carefully means noticing its silences.

1. Long-term use. The longest quantified exposure among these publications is the 48-week phase 2 obesity trial (PMID 37366315); multi-year outcomes are not described.
2. Hard clinical endpoints. Cardiovascular events, mortality and long-term organ outcomes were not the endpoints of the trials summarised here, which measured weight, glycaemia, liver fat and body composition (PMID 40291085, PMID 39318607).
3. Non-trial populations. Adolescents, pregnancy and lactation, and people excluded by trial screening criteria are not represented in these reports.
4. Unsupervised or non-pharmaceutical material. No study in this list examined RUO-labelled product, self-directed dosing, or peptide combinations outside protocol; the only active comparator in the phase 2 diabetes trial was dulaglutide 1.5 mg (PMID 37385280).
5. Discontinuation and maintenance. What happens after treatment stops was not an endpoint of the trials described above, and reviews note that questions about durability remain open (PMID 40563436).
6. Alternative routes. Only once-weekly subcutaneous administration appears in the pooled clinical evidence (PMID 39318607).

Understanding a compound at this level means holding two ideas together: the published trials reported substantial measured changes in their chosen endpoints, and those reports were produced under conditions that do not generalise automatically to any other context. Decisions about medical care belong with a licensed clinician who can weigh an individual's full picture.

References

• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Cell Metabolism, 2022)
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (Lancet, 2022)
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials (Metabolism Open, 2024)
• The power of three: Retatrutide's role in modern obesity and diabetes therapy (European Journal of Pharmacology, 2024)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings - Baylor University Medical Center, 2025)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (Lancet Diabetes & Endocrinology, 2025)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (Lancet, 2026)